## NOV TOOT W

## HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

1 m 1609

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/526,175		
371(c) Date	July 29, 2005		
First Named Inventor	Gary R. Ostroff		
Confirmation Number	6462		
Group Art Unit	1609		
Examiner Name	Pagonakis, Anna		
Attorney Docket Number	2732.1047-010		

Title CANCER THERAPY USING WHOLE GLUCAN PARTICLES AND ANTIBODIES

Therefore are sind							
	I hereby appoint						
_	ctitioners associated with Customer No. 021005						
Prac	ctitioner(s) named below:						
<del></del>							
· · · · · · · · · · · · · · · · · · ·							
as my/our attorneys/agents to prosecute the application identified above, including any continuation or divisional applications thereof, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Please recognize or change the correspondence address for the above-identified application to:							
⊠ Cus	Customer Number 021005						
Har	milton, Brook, Smith & Reynolds, P.C.						
530	0 Virginia Road						
P.O	O. Box 9133						
Cor	oncord, Massachusetts 01742-9133						
Oth	her						
Please dire	ect all telephone calls and facsimiles to:						
Name	Alice O. Carroll, Esq. Tel. No. 978-341-0036 Fax No. 978-341-0136						
I am the:							
☐ App	plicant/Inventor.						
	Authorized representative of the Assignee, [ ], of the entire interest. See 37 CFR § 3.71. A Statement under 37 CFR § 3.73(b) is enclosed.						
Authorized representative of the Assignee, Biopolymer Engineering, together with University of Louisville Research Foundation, Inc., of the entire interest. A Statement under 37 CFR § 3.73(b) is enclosed.							
SIGNATURE of Applicant or Assignee of Record							
Signature	Start Fact						
Name & Title	me & Title Steven J. Karel, Chief Technology and Operations Officer						
Date	11/9/07						



756100\_1

## STATEMENT UNDER 37 CFR § 3.73(b)

Applica	ant/Patent	ee: Gary R. Ostroff and	Gordon D. Ross (	deceased)				
Applica	ation No./	Patent No.: 10/526,175		371(c) Date:	July 29, 2005			
For:	CANCE	R THERAPY USING WHO	OLE GLUCAN P	ARTICLES AND	ANTIBODIES			
	В	opolymer Engineering (Name of Assignee)	, a	of Assignee, e.g., corporat	corporation ion, partnership, university, government agency, etc.)			
states t	hat it is							
A.		the assignee of the entire	right, title and int	erest in the patent	application identified above; or			
B.	$\boxtimes$	an assignee together with University of Louisville Research Foundation, Inc. of the entire right, title and interest in the patent application identified above.						
The rig		nd interest of the above-nar	ned assignee in th	ne patent application	n identified above is established by			
A. 🛛	An assignment from the inventor(s) of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel 016586, Frames 0839-0841, or a copy thereof is attached.							
OR								
В. 🗌	A chain of title from the inventor(s) of the patent application identified above, to the current assignee as shown below:							
	1.	From:[ The document was record Reel[]	led in the United in Frame	To: States Patent and T _[]	rademark Office at, or a copy thereof is attached.			
	2.	The document was record	led in the United	States Patent and T	rademark Office at, or a copy thereof is attached.			
	3.				rademark Office at , or a copy thereof is attached.			
	☐ Add	itional documents in the ch	nain of title are lis	ted on a supplemen	ntal sheet.			
		7 CFR 3.73(b)(1)(i), the doconcurrently is being, subr			title from the original owner to the CFR 3.11.			
The un	dersigned	(whose title is supplied be	low) is authorized	d to act on behalf o	f the assignee.			
Signatu	ıre	Staf Far						
Name:	Ste	ven J. Karel						
Title:_		ief Technology and Operat	ions Officer					
Date:_	11/	9/07						